Patent Assignment
Reel/Frame 056179/0417
Assignment of Assignor's Interest
Recorded: 2021-05-07
Pages: 28
Assignor
AGIOS PHARMACEUTICALS, INC.
Executed: 2021-03-29
Assignee
SERVIER PHARMACEUTICALS, LLC
200 PIER FOUR BOULEVARD, 7TH FLOOR, BOSTON, MASSACHUSETTS, 02110
Covered Properties
(95)
Methods of Treating Cancer Having an Aberrant Egfr or Kras Genotype
Application:
13/249,609 →
Publication:
US US20120041070A1
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
13/256,396 →
Publication:
US US20120121515A1
Therapeutically Active Compositions and Their Methods of Use
Application:
13/492,159 →
Publication:
US US20130035329A1
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
13/617,332 →
Publication:
US US20130288284A1
Methods of Identifying a Candidate Compound
Application:
13/638,881 →
Publication:
US US20130197106A1
Therapeutically Active Compositions and Their Methods of Use
Therapeutically Active Compositions and Their Methods of Use
Application:
13/810,410 →
Publication:
US US20130184222A1
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
13/939,519 →
Publication:
US US20140187435A1
Therapeutically Active Compositions and Their Methods of Use
Application:
14/126,763 →
Publication:
US US20140213580A1
Therapeutically Active Compounds and Their Methods of Use
Application:
14/341,426 →
Publication:
US US20150031627A1
Therapeutically Active Compounds and Their Methods of Use
Application:
14/373,154 →
Publication:
US US20150087600A1
Methods and Compositions for Evaluating and Treating Cell Ptoliferation-Related Diorders Having an Isocitrate Dehydrogenase Neoactive Mutation
Application:
14/504,983 →
Publication:
US US20150240286A1
Therapeutically Active Compositions and Their Methods of Use
Application:
14/988,661 →
Publication:
US US20160130298A1
Therapeutically Active Compositions and Their Methods of Use
Application:
15/064,874 →
Publication:
US US20160264621A1
Pharmaceutical Compositions of Therapeutically Active Compounds
Application:
15/125,884 →
Publication:
US US20170007661A1
Therapeutically Active Compositions and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Application:
15/196,842 →
Publication:
US US20160304556A1
Therapeutically Active Compounds and Their Methods of Use
Application:
15/347,407 →
Publication:
US US20170057994A1
Therapeutically Active Compositions and Their Methods of Use
Application:
15/377,485 →
Publication:
US US20170166541A1
Therapeutically Active Compositions and Their Methods of Use
Application:
15/481,908 →
Publication:
US US20170210749A1
Combination Therapy for Treating Malignancies
Methods of Treatment of Malignancies
Application:
15/781,019 →
Publication:
US US20200268726A1
IDH1 Inhibitors for the Treatment of Haematological Malgnancies and Solid Tumors
Application:
16/079,802 →
Publication:
US US20190046512A1
Therapy for Treating Malignancies
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
16/790,860 →
Publication:
US US20200281501A1
Combination Therapy for Treating Malignancies
Application:
16/846,976 →
Publication:
US US20200405737A1
IDH1 Inhibitors for the Treatment of Haematological Malignancies and Solid Tumors
Application:
16/869,238 →
Publication:
US US20200261434A1
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Pharmaceutical Compositions of Therapeutically Active Compounds
Therapeutically Active Compounds and Their Methods of Use
Therapy for Treating Malignancies
Application:
17/203,433 →
Publication:
US US20210205281A1
Methods and Compositions for Treating Cancer
Application:
61/160,664 →
Methods of Treating Cancer Having an Aberrant Egfr or Kras Genotype
Application:
61/165,387 →
Methods and Compositions for Treating Cancer
Application:
61/173,518 →
Methods of Treating Cancer Having Somatic Mutations of the Isocitrate Dehydrogenase Gene
Application:
61/180,609 →
Methods and Compositions for Treating Cancer
Application:
61/220,543 →
Methods and Compositions for Treating Cancer
Application:
61/227,649 →
Methods and Compositions for Treating Cancer
Application:
61/229,689 →
Methods and Compositions for Cell-Proliferation-Related Disorders Characterized by a Neoactive Mutation at Residue 97 of IDH1 or at Residue 137 of IDH2
Application:
61/253,818 →
Methods and Compositions for Cell-Proliferation-Related-Disorders
Application:
61/253,820 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
61/253,821 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
61/266,929 →
Methods and Compositions for Cell-Proliferation-Related Disorders
Application:
61/266,930 →
Therapeutically active compositions and their methods of use
Application:
61/285,122 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/313,532 →
Methods of Identifying a Candidate Compound
Application:
61/320,255 →
Methods of Identifying a Candidate Compound
Application:
61/331,322 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/365,072 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/584,210 →
Use of E-Cadherin and Vimentin for Selection of Treatment Responsive Patients
Application:
61/702,091 →
Therapeutic Compounds and Compositions
Application:
61/714,179 →
Compounds and Their Methods of Use
Application:
61/729,321 →
Use of E-Cadherin and Vimentin for Selection of Treatment Responsive Patients
Application:
61/805,512 →
Therapeutically Active Compounds and Their Methods of Use
Application:
61/845,286 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/942,170 →
Therapeutically Active Compositions and Their Methods of Use
Application:
61/942,172 →
Pharmaceutical Compositions of Therapeutically Active Compounds and Their Methods of Use
Application:
61/953,480 →
Therapeutically Active Compounds and Their Methods of Use
Application:
62/081,537 →
Combination Therapy for Treating Malignancies
Application:
62/242,267 →
Combination Therapy for Treating Malignancies
Application:
62/242,282 →
Combination Therapy for Treating Malignancies
Application:
62/255,253 →
Therapy for Treating Malignancies
Application:
62/682,808 →
Therapeutically Active Compounds and Their Methods of Use
Application:
63/149,075 →
Compounds and Their Methods of Use
Glutaminase Inhibitors and Method of Use
Therapeutically Active Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Compounds and Their Methods of Use
Methods of Evaluating Patients Using E-Cadherin or Vimentin
Therapeutically Active Compounds and Their Methods of Use
Therapeutic Compounds and Compositions
2,4- or 4,6-Diaminopyrimidine Compounds as IDH2 Mutants Inhibitors for the Treatment of Cancer
Glutaminase Inhibitors and Method of Use
Pharmaceutical Compositions of Therapeutically Active Compounds
Methods and Compositions for Cell-Proliferation-Related Disorders
Therapeutically Active Compositions and Their Methods of Use
Combination Therapy for Treating Malignancies
Compounds and Their Methods of Use
Therapeutically Active Compounds and Their Methods of Use
Methods for Diagnosing Idh-Mutant Cell Proliferation Disorders
Therapeutically Active Compounds and Their Methods of Use
Pharmaceutical Compositions of Therapeutically Active Compounds
Therapeutically Active Compounds and Their Methods of Use
Method for Diagnosing Cell Proliferation Disorders Having a Neoactive Mutation at Residue 97 of Isocitrate Dehydrogenase 1
Compounds and Their Methods of Use
Compounds and Their Methods of Use
Methods and Compositons for Cell-Proliferation-Related Disorders
Therapeutically Active Compounds and Their Methods of Use
Methods of Evaluating Patients Using E-Cadherin and Vimentin
Phenyl and Pyridinyl Substituted Piperidines and Piperazines as Inhibitors of IDH1 Mutants and Their Use in Treating Cancer
Therapeutically Active Compositions and Their Methods of Use
Pharmaceutical Compositions of Therapeutically Active Compounds
Method for Treating Cell Proliferation Related Disorders
Methods of Treating Cancer Having Somatic Mutations of the Isocitrate Dehydrogenase Gene
Application:
61/160,253 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 1, 2011
From: JIN, SHENGFANG; SU, SHINSAN; VAN DER HEIDEN, MATTHEW
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 027157/0633 →
Assignment of Assignor's Interest
Nov 2, 2011
From: DANG, LENNY; FANTIN, VALERIA; GROSS, STEFAN; GYUNG, HYUN
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 027163/0548 →
Assignment of Assignor's Interest
Aug 21, 2012
From: SAUNDERS, JEFFREY O.; SALITURO, FRANCESCO G.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 028821/0742 →
Assignment of Assignor's Interest
Oct 12, 2012
From: SAUNDERS, JEFFREY O.; SALITURO, FRANCESCO G.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 029122/0396 →
Assignment of Assignor's Interest
Oct 23, 2012
From: FANTIN, VALERIA; SU, SHIN-SAN MICHAEL
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 029171/0947 →
Assignment of Assignor's Interest
Mar 28, 2013
From: SCHRODINGER, LLC.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 030105/0940 →
Assignment of Assignor's Interest
Mar 28, 2013
From: YAN, SHUNQI
To: SCHRODINGER, LLC
Reel/Frame 030105/0928 →
Assignment of Assignor's Interest
Mar 28, 2013
From: POPOVICI-MULLER, JANETA; SALITURO, FRANCESCO GERALD; SAUNDERS, JEFFREY O.; TRAVINS, JEREMY
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 030105/0960 →
Assignment of Assignor's Interest
Dec 9, 2015
From: LEMIEUX, RENE M.; POPOVICI-MULLER, JANETA; TRAVINS, JEREMY
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 037252/0296 →
Assignment of Assignor's Interest
Dec 9, 2015
From: PHARMARESOURCES (SHANGHAI) CO., LTD.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 037252/0420 →
Assignment of Assignor's Interest
Dec 9, 2015
From: CAI, ZHENWEI; CUI, DAWEI; ZHOU, DING
To: PHARMARESOURCES (SHANGHAI) CO., LTD.
Reel/Frame 037252/0365 →
Assignment of Assignor's Interest
Apr 27, 2016
From: PHARMARESOURCES (SHANGHAI) CO., LTD.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 038398/0301 →
Assignment of Assignor's Interest
Apr 27, 2016
From: CAI, ZHENWEI; CUI, DAWEI; ZHOU, DING
To: PHARMARESOURCES (SHANGHAI) CO., LTD.
Reel/Frame 038398/0263 →
Assignment of Assignor's Interest
Apr 27, 2016
From: LEMIEUX, RENE MARC; POPOVICI-MULLER, JANETA; TRAVINS, JEREMY
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 038398/0208 →
Assignment of Assignor's Interest
Jun 29, 2016
From: PHARMARESOURCES (SHANGHAI) CO., LTD.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 039208/0961 →
Assignment of Assignor's Interest
Jun 29, 2016
From: SCHRODINGER, LLC.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 039046/0633 →
Assignment of Assignor's Interest
Jun 29, 2016
From: POPOVICI-MULLER, JANETA; SAUNDERS, JEFFREY O.; SALITURO, FRANCESCO G.
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 039046/0643 →
Assignment of Assignor's Interest
Jun 29, 2016
From: CAI, ZHENWEI; ZHOU, DING
To: PHARMARESOURCES (SHANGHAI) CO., LTD.,
Reel/Frame 039207/0993 →
Assignment of Assignor's Interest
Jun 29, 2016
From: PHARMARESOURCES (SHANGHAI) CO., LTD.
To: AGIOS PHARMACEUTICALS, INC.,
Reel/Frame 039208/0005 →
Assignment of Assignor's Interest
Jun 29, 2016
From: CAI, ZHENWEI; ZHOU, DING
To: PHARMARESOURCES (SHANGHAI) CO., LTD.
Reel/Frame 039208/0891 →
Assignment of Assignor's Interest
Sep 27, 2016
From: POPOVICI-MULLER, JANETA; SALITURO, FRANCESCO G.; SAUNDERS, JEFFREY O.; TRAVINS, JEREMY
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 039871/0158 →
Assignment of Assignor's Interest
Sep 27, 2016
From: YAN, SHUNQI
To: SCHRÖDINGER, LLC
Reel/Frame 039871/0165 →
Assignment of Assignor's Interest
Sep 27, 2016
From: SCHRÖDINGER, LLC
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 039871/0168 →
Assignment of Assignor's Interest
Feb 15, 2017
From: YAN, SHUNQI
To: SCHRODINGER, LLC
Reel/Frame 041261/0107 →
Assignment of Assignor's Interest
Feb 15, 2017
From: SCHRODINGER, LLC
To: AGIOS PHARMACEUTICALS, INC
Reel/Frame 041261/0135 →